Days of literature review.
Minutes with Clarisyn.
A real compound. A real question. A real answer.
The Scenario
The Question
"Predict the metabolic fate of the following compound (CAS No. 84057-84-1; SMILES: C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N), a triazine-based scaffold bearing a 2,3-dichlorophenyl group and an aminopyrazole moiety. Focus on CYP-mediated bioactivation pathways, potential reactive intermediate formation, and implications for genotoxicity or covalent protein adduction. Recommend mechanistic follow-up studies to characterise the risk."
Layer 1· Intelligence Report
CYP-mediated bioactivation, reactive intermediate formation, and genotoxicity risk. Clarisyn returned a full synthesis of the evidence, key mechanistic findings first, then the literature in depth. Where agents reached different conclusions on the primary CYP isoform responsible, both perspectives were surfaced and flagged.
Layer 2· Reasoning & Process
How the analysis was prioritised and why. Follow-up studies ranked by mechanistic gap significance and regulatory impact, with the full decision logic shown at each step.
Layer 3· Evidence & Sources
Published literature, drug and chemical data, and computational sources, all cited and traceable. Every claim in the report linked back to where it came from.
"Clarisyn turns days of literature review into minutes, delivering a structured, reliable report that is immediately usable. Where deeper expert interpretation is needed, a built-in consultation pathway transforms it from a starting point into a genuine collaborative tool."
Prof. Alan Boobis, OBE
Emeritus Professor of Toxicology, Imperial College London.
Former Chair, UK Committee on Toxicity.